about
Dysregulated serum response factor triggers formation of hepatocellular carcinomaFLT3 as a therapeutic target in AML: still challenging after all these yearsAddition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.Epigenetic stress responses induce muscle stem-cell ageing by Hoxa9 developmental signals.Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia.Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells.Identification of DNA methylation changes at cis-regulatory elements during early steps of HSC differentiation using tagmentation-based whole genome bisulfite sequencingEpigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia.CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia.Epo-induced erythroid maturation is dependent on Plcγ1 signaling.Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias.Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.Dissection of CD20 regulation in lymphoma using RNAi.[Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets].Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis.RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats.Erratum: DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats.Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis.Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer.The transcriptomic and epigenetic map of vascular quiescence in the continuous lung endothelium.Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381)LaminA/C regulates epigenetic and chromatin architecture changes upon aging of hematopoietic stem cellsDifferential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cellsFrom Basic Knowledge to Effective TherapiesMethylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLLIntegrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic CholangiocarcinomaAzacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemiaHepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AMLAuthor Correction: Epigenetic stress responses induce muscle stem-cell ageing by Hoxa9 developmental signalsHistone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic targetGermline SDHB-inactivating mutation in gastric spindle cell sarcoma
P50
Q28390147-93135E5A-AEBB-43F6-8B2A-57B51CFCD220Q29042570-9F2F3190-2BBF-4496-93DB-AEA00AD3DC30Q33374067-1FDCC964-3F06-4B94-8884-0690F55DA836Q33633254-686CA41D-C138-432D-A18C-48558AC16236Q33772607-11A24025-F098-44D1-A583-9A8E50E39DACQ36095789-DACA4900-59F1-4BA5-869F-0097E4BA293DQ36183871-E66C8971-71E8-4FAD-8ACF-CBDDB147F362Q36838867-35A0D930-47A8-4F6B-990C-29F3E3CB4AE0Q39784106-E4154516-AB18-44D8-8514-39F0353009B2Q40386692-30E9E336-B30A-4B06-83F2-BAA26A56C261Q41387385-CA130167-8586-40A2-A053-540B662E499CQ42609684-A56D6687-95A2-474F-8FE0-EBBCA0CFEA81Q43284509-3632F61B-D1C0-4FB9-8A0C-275DBFE8F48DQ46372937-E4BFE045-4CE0-45E4-A775-F37AC2D8EF72Q46409603-10E20664-C5C3-4E82-8A4D-5DB1BD462914Q46456469-E0C749C9-53EF-4428-9603-DD16E1235C10Q47098092-D51A8269-E172-408E-BE8E-44B03C9ADFC2Q47134904-D7A46AA2-50E8-45A1-828A-F858BA5AEC37Q48293367-56C150DE-2B3F-4EB5-982C-E6B9378957E7Q50092779-6B259DF3-6C86-4C6D-AFF6-2558F8A4535AQ50426562-10533DA2-B6F4-4A65-B526-38F9335A2251Q51064042-B55078DB-B44B-436B-B904-AF1025C0DF45Q53819472-3E240786-07E3-45F8-BB05-6DF5488CE7B9Q57782667-FDF67ADF-B0B4-4AE9-A3C7-F1FFBE811ED8Q58595443-9F86296B-0F47-4088-9FC4-3FBE646CA6DBQ64085667-79024455-8CE1-4B0D-B742-E355807621A6Q84865702-EBC8F02F-CE88-49CA-8691-336D5AA1EBBEQ90407421-29782D97-8972-4483-826B-30CA4207ED43Q90436072-C6DB97D3-F931-48D0-A90B-4EEA9D1A29F5Q90919779-A103AD39-FE63-48CC-8B00-2F58E0FB1FD8Q91212022-6290C591-BB48-4E6D-944F-D67EA9C4621EQ91929066-8DE0A99D-B6A2-4B5C-93E9-46D8847D9FD1Q92297332-E4A218BD-A58C-432C-AA07-48DA82B0CE52Q92312939-44237232-EC0C-4206-9063-1B5082B35650Q96163691-B3CFDED4-EDD1-4AED-9144-5D54CC87BE9E
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Daniel B Lipka
@en
Daniel B Lipka
@nl
type
label
Daniel B Lipka
@en
Daniel B Lipka
@nl
prefLabel
Daniel B Lipka
@en
Daniel B Lipka
@nl
P31
P496
0000-0001-5081-7869